izpis_h1_title_alt

Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line
ID Kljun, Jakob (Author), ID Pavlič, Renata (Author), ID Hafner, Eva (Author), ID Lipec, Tanja (Author), ID Moreno-Da Silva, Sara (Author), ID Tič, Primož (Author), ID Turel, Iztok (Author), ID Büdefeld, Tomaž (Author), ID Stojan, Jure (Author), ID Lanišnik-Rižner, Tea (Author)

.pdfPDF - Presentation file, Download (1,85 MB)
MD5: 13059C55BAB912588925086FA0DB8B0D
URLURL - Source URL, Visit https://www.frontiersin.org/articles/10.3389/fphar.2022.920379/full This link opens in a new window

Abstract
In this study, we present the synthesis, kinetic studies of inhibitory activity toward aldo-keto reductase 1C (AKR1C) enzymes, and anticancer potential toward chemoresistant ovarian cancer of 10 organoruthenium compounds bearing diketonate (1–6) and hydroxyquinolinate (7–10) chelating ligands with the general formula [(η$^6$-p-cymene)Ru(chel)(X)]$^{n+}$ where chel represents the chelating ligand and X the chlorido or pta ligand. Our studies show that these compounds are potent inhibitors of the AKR enzymes with an uncommon inhibitory mechanism, where two inhibitor molecules bind to the enzyme in a first fast and reversible step and a second slower and irreversible step. The binding potency of each step is dependent on the chemical structure of the monodentate ligands in the metalloinhibitors with the chlorido complexes generally acting as reversible inhibitors and pta complexes as irreversible inhibitors. Our study also shows that compounds 1–9 have a moderate yet better anti-proliferative and anti-migration action on the chemoresistant ovarian cancer cell line COV362 compared to carboplatin and similar effects to cisplatin.

Language:English
Keywords:ruthenium complexes, synthesis, crystal structure, anticancer, aldo-keto reductase, enzyme inhibition
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FKKT - Faculty of Chemistry and Chemical Technology
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:15 str.
Numbering:Vol. 13, art. 920379
PID:20.500.12556/RUL-145365 This link opens in a new window
UDC:618.1
ISSN on article:1663-9812
DOI:10.3389/fphar.2022.920379 This link opens in a new window
COBISS.SI-ID:115794691 This link opens in a new window
Publication date in RUL:19.04.2023
Views:575
Downloads:75
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in pharmacology
Shortened title:Front Pharmacol
Publisher:Frontiers Media
ISSN:1663-9812
COBISS.SI-ID:29551833 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:rutenijevi kompleksi, sinteza, kristalna struktura

Projects

Funder:ARRS - Slovenian Research Agency
Project number:J3-2535
Name:Vloga androgenov pri hormonsko odvisnih boleznih: pomen za diagnostiko in zdravljenje

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Funder:ARRS - Slovenian Research Agency
Project number:P1-0175
Name:Napredna anorganska kemija

Funder:ARRS - Slovenian Research Agency
Project number:Z1-6735
Name:Nove tarče za stare učinkovine – organorutenijevi derivati hidroksikinolinov in beta-karbolinov kot potencialna protirakava sredstva

Funder:ARRS - Slovenian Research Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back